Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia

24 Apr 2023

Abstract excerpt

BH3 mimetics are used as an efficient strategy to induce cell death in several blood malignancies, including acute myeloid leukemia (AML). Venetoclax, a potent BCL-2 antagonist, is used clinically in combination with hypomethylating agents for the treatment of AML. Moreover, MCL1 or dual BCL-2/BCL-xL antagonists are under investigation. Yet, resistance to single or combinatorial BH3-mimetic therapies eventually...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Autophagy in Disease and Therapy
Share to Cell death mechanisms and regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37088914
DOI: 10.1158/2159-8290.cd-22-0601

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid LeukemiaPMID 37088914Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity Read ↗

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AMLSemantic proximity Read ↗

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML CellsSemantic proximity Read ↗

The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicineSemantic proximity Read ↗

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugsSemantic proximity Read ↗

Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity Read ↗

Mitochondria and Acute Leukemia: A Clinician’s PerspectiveSemantic proximity Read ↗

BCL2 and MCL1 inhibitors for hematologic malignanciesSemantic proximity Read ↗

Venetoclax resistance: mechanistic insights and future strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.